X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
Details:
ANK-101 is an anchored drug complex composed of interleukin-12 (IL-12) linked to aluminum hydroxide. It is being evaluated for the treatment of solid tumors.
Lead Product(s): ANK-101,Aluminium Hydroxide
Therapeutic Area: Oncology Product Name: ANK-101
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2024
Details:
AD04 (alhydrogel) is a novel immunotherapy for early alzheimer’s disease. The compound has been used as an adjuvant in human and animal vaccination programs. It has demonstrated significantly slower decline in hippocampal volume as a biomarker.
Lead Product(s): Aluminium Hydroxide
Therapeutic Area: Neurology Product Name: AD04
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
Details:
AD04™ (alhydrogel) is a novel immunotherapy for mild Alzheimer’s Disease under the Innovative Licensing and Access Pathway (ILAP). AD04™ also showed slower decline in hippocampal volume as a biomarker.
Lead Product(s): Aluminium Hydroxide
Therapeutic Area: Neurology Product Name: AD04
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2023
Details:
AD04™ (alhydrogel) is a novel immunotherapy for early alzheimer’s disease. The compound has been used as an adjuvant in human and animal vaccination programs. It has demonstrated significantly slower decline in hippocampal volume as a biomarker.
Lead Product(s): Aluminium Hydroxide
Therapeutic Area: Neurology Product Name: AD04
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2023
Details:
SCB-2019 antigen, a stabilized trimeric form of the S-protein based on the original strain of the SARS-CoV-2 virus, and combined it with Dynavax’s CpG 1018 advanced adjuvant and aluminum hydroxide (alum). Clover is developing it as a universal booster for COVID-19.
Lead Product(s): CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: SCB-2019
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
Details:
SCB-2019 antigen, a stabilized trimeric form of the S-protein based on the original strain of the SARS-CoV-2 virus, and combined it with Dynavax’s CpG 1018 advanced adjuvant and aluminum hydroxide (alum). Clover is developing it as a universal booster for COVID-19.
Lead Product(s): CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: SCB-2019
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 15, 2023
Details:
VLA2001 consists of inactivated whole virus particles of SARS-CoV-2 with high S-protein density, in combination with two adjuvants, alum and CpG 1018. VLA2001’s shelf life is expected to be extended to up to 24 months, compared to 18 months currently.
Lead Product(s): VLA2001,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 30, 2022
Details:
Emergent BioSolutions’ CHIKV VLP chikungunya virus vaccine candidate is a single dose VLP-based vaccine in clinical development for active immunization against chikungunya disease.
Lead Product(s): CHIKV VLP,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: PXVX0317
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: CDMRP
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Funding November 14, 2022
Details:
PXVX0317 (CHIKV VLP) chikungunya virus vaccine candidate is a single dose VLP-based vaccine in clinical development for active immunization against chikungunya disease.
Lead Product(s): CHIKV VLP,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: PXVX0317
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2022
Details:
SCB-2019 (CpG 1018) antigen, a stabilized trimeric form of the S-protein is based on the original strain of the SARS-CoV-2 virus. Clover created its COVID-19 vaccine candidate by combining SCB-2019 with Dynavax’s CpG 1018 advanced adjuvant and alum.
Lead Product(s): CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: SCB-2019
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2022
Details:
VLA2001 is produced on Valneva’s established Vero-cell platform, leveraging technology. VLA2001 consists of inactivated whole virus particles of SARS-CoV-2 with high S-protein density, in combination with two adjuvants, alum and CpG 1018.
Lead Product(s): VLA2001,CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Valneva
Deal Size: $39.9 million Upfront Cash: $35.5 million
Deal Type: Termination September 16, 2022
Details:
VLA2001 consists of inactivated whole virus particles of SARS-CoV-2 with high S-protein density, in combination with two adjuvants, alum and CpG 1018.
Lead Product(s): VLA2001,CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022
Details:
In both the homologous and heterologous setting, VLA2001 was able to boost immunity to higher neutralizing antibody titers than following priming, and to levels reported to be highly efficacious (90%) against SARS-CoV-2.
Lead Product(s): VLA2001,CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2022
Details:
SCB-2019 (CpG 1018/Alum) elicited approximately 2-fold higher neutralizing antibody titers in adolescents (aged 12 to 17 years) compared to young adults (aged 18 to 25 years).
Lead Product(s): CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: SCB-2019
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2022
Details:
SCB-2019 (CpG 1018/Alum) as a third dose exhibited a 19-fold boost in neutralizing antibodies against Omicron BA.2 variant among baseline seronegative participants.
Lead Product(s): CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: SCB-2019
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2022
Details:
VLA2001 is the only whole virus, inactivated, adjuvanted COVID-19 vaccine which has received marketing authorization in Europe for use as primary vaccination in people from 18 to 50 years of age.
Lead Product(s): VLA2001,CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2022
Details:
VLA2001 consists of inactivated whole virus particles of SARS-CoV-2 with high S-protein density, in combination with two adjuvants, alum and CpG 1018.
Lead Product(s): VLA2001,CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2022
Details:
Emergent’s PXVX0317 (CHIKV VLP) vaccine candidate was well tolerated and induced a robust and durable serum neutralizing antibody immune response against the Chikungunya virus up to two years.
Lead Product(s): CHIKV VLP,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: PXVX0317
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2022
Details:
SCB-2019 (CpG 1018/Alum), employing the Trimer-Tag™ technology platform, Clover developed the SCB-2019 antigen, a stabilized trimeric form of the S-protein (referred to as S-Trimer™) based on the original strain of the SARS-CoV-2 virus.
Lead Product(s): CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: SCB-2019
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2022
Details:
VLA2001 consists of inactivated whole virus particles of SARS-CoV-2 with high S-protein density, in combination with two adjuvants, alum and CpG 1018.
Lead Product(s): VLA2001,CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2022
Details:
SCB-2020S is a second generation, potentially broadly protective COVID-19 vaccine candidate based on a chimeric Beta and prototype trimeric SARS-CoV-2 S-protein, preserving potential neutralization epitopes across multiple variants of concern of SARS-CoV-2, including Omicron.
Lead Product(s): SCB-2020S,CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: SCB-2020S
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2022
Details:
VLA2001 consists of inactivated whole virus particles of SARS-CoV-2 with high S-protein density, in combination with two adjuvants, alum and CpG 1018. This adjuvant combination has consistently induced higher antibody levels in preclinical than alum-only formulations.
Lead Product(s): VLA2001,CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2022
Details:
The Company will work with the EC and the participating EC member states to agree to a remediation plan and to make VLA2001 available to those member states who still wish to receive it.
Lead Product(s): VLA2001,CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: European Commission
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination May 16, 2022
Details:
VLA2001, only whole virus, inactivated, adjuvanted vaccine candidate, may also be suited for boosting, as repeat booster vaccinations have been shown to work well with whole virus inactivated vaccines.
Lead Product(s): VLA2001,CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2022
Details:
The increased funding will be used to further invest in R&D, including market access preparations for Valneva’s chikungunya vaccine candidate, VLA1553 and VLA2001.
Lead Product(s): VLA2001,CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Deerfield Management Company
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing April 26, 2022
Details:
Positive data for SCB-2019 demonstrated durable protection through approximately six month following primary vaccination and robust immune response in neutralizing Omicron and other variant of concern after a booster dose in an expanded data set involving over 100 participant.
Lead Product(s): CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: SCB-2019
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2022
Details:
Albumedix Recombumin® rHA is an essential component in VLA2001, used in the manufacturing process and final formulation of the vaccine. VLA2001 is produced on Valneva’s established Vero-cell platform, leveraging the manufacturing technology.
Lead Product(s): VLA2001,CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Valneva
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration April 14, 2022
Details:
VLA2001 is only whole virus, inactivated, adjuvanted vaccine candidate in Europe, intended for active immunization of at-risk populations to prevent carriage and symptomatic infection with COVID-19 during pandemic and for routine vaccination.
Lead Product(s): VLA2001,CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2022
Details:
Clover developed the SCB-2019 antigen, a stabilized trimeric form of the S-protein based on original strain of the SARS-CoV-2 virus. Clover created its COVID-19 vaccine candidate by combining SCB-2019 with Dynavax’s CpG 1018 advanced adjuvant and alum.
Lead Product(s): SCB-2019 Antigen,CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: SCB-2019
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2022
Details:
100% efficacy maintained against severe COVID-19 and 95% efficacy against hospitalization at five months after second dose of a stabilized trimeric form of the S-protein SCB-2019 (CpG 1018/Alum).
Lead Product(s): SCB-2019 Antigen,CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: SCB-2019
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2022
Details:
VLA2001, inactivated, adjuvanted vaccine candidate in clinical trials against COVID-19 in Europe, is intended for active immunization to prevent carriage and symptomatic infection with COVID-19 during pandemic and for routine vaccination including addressing new variants.
Lead Product(s): VLA2001,CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2022
Details:
The first grant will support research and development related to the manufacture of VLA2001, Valneva’s inactivated, whole virus COVID-19 vaccine candidate. The second grant will support research and development connected to Valneva.
Lead Product(s): VLA2001,CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Scottish Enterprise
Deal Size: $27.2 million Upfront Cash: Undisclosed
Deal Type: Funding February 21, 2022
Details:
The trial extension will evaluate a booster dose of VLA2001 in adults, aged 18 and above, who received primary vaccination with two doses of VLA2001, as well as participants, aged 30 and above, who received two doses of AstraZeneca’s (AZD1222).
Lead Product(s): VLA2001,CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2022
Details:
SCB-2019 (CpG 1018/Alum) achieved the primary efficacy endpoint and secondary efficacy endpoint, also demonstrated 100% efficacy against severe COVID-19 and hospitalization caused by any strain of SARS-CoV-2 in SPECTRA phase 2/3 trial trial.
Lead Product(s): CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: SCB-2019
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 21, 2022
Details:
Preliminary laboratory studies demonstrate that three doses of Valneva’s inactivated COVID-19 vaccine candidate VLA2001, shown neutralizing antibodies against the ancestral virus and Delta variant, and 87% against the Omicron variant.
Lead Product(s): VLA2001,CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2022
Details:
Company is expecting potential regulatory approvals in the first quarter of 2022 for VLA2001 an whole virus, inactivated, adjuvanted vaccine candidate, on the basis of announced positive homologous booster results.
Lead Product(s): VLA2001,CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2022
Details:
The manufacturing process for VLA2001, which has already been upscaled to final industrial scale, includes chemical inactivation to preserve the native structure of the S-protein. VLA2001 is expected to conform with standard cold chain requirements (2 to 8 degrees Celsius).
Lead Product(s): VLA2001,CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Kingdom of Bahrain
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 08, 2021
Details:
Valneva believes it is likely that the short interval between the second shot and booster shot could have adversely impacted the results for VLA2001, given that a longer interval is generally required for inactivated vaccines.
Lead Product(s): VLA2001,CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 03, 2021
Details:
Clover’s COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum), will be assessed as a heterologous booster dose in individuals previously vaccinated with either CoronaVac or recombinant Covid-19 vaccine (AstraZeneca/Fiocruz).
Lead Product(s): CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: SCB-2019
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: IDOR
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2021
Details:
Under the terms of the agreement following final review of the volumes by each of the European Union (EU) Member States, Valneva expects to deliver 24.3 million doses during the second and third quarters of 2022, subject to approval of VLA2001 by the European Medicines Agency.
Lead Product(s): VLA2001,CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: European Commission
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 23, 2021
Details:
VLA2001 consists of inactivated whole virus particles of SARS-CoV-2 with high S-protein density, in combination with two adjuvants, alum and CpG 1018 used to prevent carriage and symptomatic infection with COVID-19.
Lead Product(s): VLA2001,CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: European Commission
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 10, 2021
Details:
Valneva has developed VLA2001, currently the only whole virus, inactivated, adjuvanted vaccine candidate in clinical trials against COVID-19 in Europe.
Lead Product(s): VLA2001,CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 08, 2021
Details:
VLA2001 is currently the only whole virus, inactivated, adjuvanted vaccine candidate in clinical trials against COVID-19 in Europe.
Lead Product(s): VLA2001,CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Goldman Sachs & Co. LLC
Deal Size: $102.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 01, 2021
Details:
VLA2001 is inactivated, adjuvanted COVID-19 vaccine candidate, produced on Valneva’s established Vero-cell platform. VLA2001 successfully met both co-primary endpoints demonstrated superiority against AZD1222, in terms of geometric mean titer for neutralization antibodies.
Lead Product(s): VLA2001,CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2021
Details:
VLA2001 is currently the only whole virus, inactivated, adjuvanted vaccine candidate in clinical trials against COVID-19 in Europe. Valneva is conducting several clinical trials of VLA2001, such as VLA2001-201, and VLA2001 is being evaluated as VLA2001-304 in New Zealand.
Lead Product(s): VLA2001,CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 23, 2021
Details:
SCB-2019 (CpG 1018/Alum) demonstrated 79% overall efficacy against COVID-19 of any severity caused by the globally dominant Delta variant.
Lead Product(s): CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: SCB-2019
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2021
Details:
300 volunteers aged 56 years and older have been recruited in New Zealand into the VLA2001-304 trial with the objective to generate further safety and immunogenicity data for this age group.
Lead Product(s): VLA2001,CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2021
Details:
Under Dynavax's existing supply agreement for CpG 1018, purchase orders submitted by Valneva are cancellable if the UK Government reduces or terminates its order for VLA2001, in which case, Valneva would not be obligated to pay Dynavax the final portion of purchase order.
Lead Product(s): VLA2001,CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Dynavax Technologies
Deal Size: $1.4 million Upfront Cash: Undisclosed
Deal Type: Termination September 13, 2021
Details:
HMG has alleged that the Company is in breach of its obligations under the Supply Agreement, but the Company strenuously denies this. Valneva is continuing its VLA2001 development plan. VLA2001 is in phase 3 trials with results due in the fourth quarter.
Lead Product(s): VLA2001,CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: UK Government
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination September 13, 2021
Details:
BBIL’s BBV87 vaccine is an inactivated whole virion vaccine based on strain derived from an East, Central, South African (ECSA) genotype. IVI is advancing clinical development of BBV87 to evaluate safety and immunogenicity of 2-dose regimen of BBV87 Chikungunya vaccine.
Lead Product(s): Whole Inactivated Virus,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: BBV87
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: The International Vaccine Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
